Search Results - O V Kalashnikova
- Showing 1 - 12 results of 12
-
1
Methodological features of the analysis and estimation of economic security based on the state financial regulation of health care of the Russian Federation by E. B. Krylova, O. V. Kalashnikova
Published 2020-01-01The article discusses the methodological features of analyzing and assessing economic security depending on the degree of influence of state financial regulation in the health sector, including principles, methods for analyzing the effectiveness ofthe mechanism for financial support of medical organ...
Get full text
Article -
2
How to identify a patient with autoinflammatory syndrome: Clinical and diagnostic algorithms by Mikhail Mikhailovich Kostik, L S Snegireva, M F Dubko, V V Masalova, T S Likhacheva, O V Kalashnikova, V G Chasnyk
Published 2013-10-01Autoinflammatory syndromes (AISs) are a group of predominantly hereditary diseases associated with the spontaneous uncontrolled production of proinflammatory cytokines. Most diseases are known to have molecular mechanisms and an inheritance pattern. The paper describes major AISs, such as familial M...
Get full text
Article -
3
Evaluation of the efficiency and safety of tocilizumab therapy in patients with systemic-onset juvenile idiopathic arthritis: results of a retrospective follow-up by M. M. Kostik, E. A. Isupova, I. A. Chikova, M. F. Dubko, V. V. Masalova, L. S. Snegireva, O. V. Kalashnikova, V. G. Chasnyk
Published 2018-01-01Objective: to study the efficiency and safety of tocilizumab (TCZ) therapy in patients with systemic-onset juvenile idiopathic arthritis (sJIA). Patients and methods. The retrospective study included 48 children with active sJIA in whom TCZ therapy was initiated because of the inefficiency of using...
Get full text
Article -
4
Current approaches to diagnosing and treating macrophage activation syndrome in children with rheumatic diseases by M. M. Kostik, M. F. Dubko, V. V. Masalova, L. S. Snegireva, I. A. Chikova, E. A. Isupova, O. V. Kalashnikova, V. G. Chasnyk
Published 2015-03-01Macrophage activation syndrome (MAS) is a severe life-threatening complication presenting with hemophagocytosis, pancytopenia, coagulopathy, and liver and CNS dysfunctions. The disease belongs to a group of histiocytic disorders. The common triggers for MAS are rheumatic diseases, particularly syste...
Get full text
Article -
5
NLRP12-associated periodic syndrome: A description of the authors' own observation and an analysis of literature data by M. F. Dubko, E. N. Suspitsyn, A. P. Sokolenko, E. N. Imyanitov, T. S. Likhacheva, A. Yu. Kazantseva, O. V. Kalashnikova, V. G. Chasnyk, M. M. Kostik
Published 2017-04-01Autoinflammatory diseases (AIDs) are a group of rare disorders characterized by persistent or recurrent inflammation caused by the hyperactivation of mediators and innate immune cells (neutrophils, monocytes/macrophages). The paper describes the authors' own case of NLRP12-associated AIDs and t...
Get full text
Article -
6
The Efficiency of Adalimumab in Cases of Chronic Methotrexate-Resistant Juvenile Idiopathic Arthritis-Associated Anterior Uveitis: Retrospective Case Series Study by E. V. Gaidar, M. M. Kostik, M. F. Dubko, V. V. Masalova, L. S. Snegireva, E. A. Isupova, T. N. Nikitina, E. D. Serogodskaya, O. V. Kalashnikova, V. G. Chasnyk
Published 2016-11-01Background: Juvenile idiopathic arthritis (JIA) associated uveitis may be the cause of not only visual acuity decrement, but also blindness. At the same time, in some patients therapy with methotrexate can not prevent the development of these complications.Objective: Our aim was to investigate the e...
Get full text
Article -
7
Comparison of different treatment modalities of tocilizumab in children with systemic juvenile idiopathic arthritis by M. M. Kostik, M. F. Dubko, L. S. Snegireva, V. V. Masalova, T. L. Kornishina, T. S. Likhacheva, I. A. Chikova, E. A. Isupova, E. M. Kuchinskaya, N. I. Glebova, O. V. Kalashnikova, V. G. Chasnykh
Published 2013-09-01Aim: to perform retrospective evaluation of tocilizumab (TCZ) treatment every 2 and 4 weeks. Patients and methods: 33 children with systemic juvenile idiopathic arthritis (sJIA) were observed. Results: children, who need TCZ treatment every 2 weeks had more severe sJIA course. Patients which were tr...
Get full text
Article -
8
Can the Methotrexate Therapy Prevent the Development of Uveitis in Patients with Juvenile Idiopathic Arthritis: Results of a Retrospective Study by M. M. Kostik, E. V. Gaydar, M. F. Dubko, V. V. Masalova, L. S. Snegireva, I. A. Chikova, E. A. Isupova, T. N. Nikitina, E. D. Serogodskaya, O. V. Kalashnikova, A. Ravelli, V. G. Chasnyk
Published 2015-09-01Background: Uveitis is one of the most common extra-articular manifestations of juvenile idiopathic arthritis (JIA). Currently, the possibility of reducing the risk of uveitis in children with JIA by using methotrexate has been studied.Objective: Our aim was to analyze the results of treatment of ch...
Get full text
Article -
9
PACHYDERMODACTYLY IN A RHEUMATOLOGIST'S PRACTICE by I. A. Chikova, M. M. Kostik, E. V. Sinelnikova, M. F. Dubko, O. I. Krasnogorskaya, A. I. Imelbaev, R. N. Polozov, N. V. Buchinskaya, E. A. Isupova, E. V. Gaidar, O. V. Kalashnikova, R. A. Nasyrov, V. G. Chasnyk
Published 2015-09-01Pachydermodactyly is a rare form of fibromatosis, which is characterized by an asymptomatic soft tissue enlargement around the proximal interphalangeal (PIP) joints of the hand. The etiology of the disease is unknown. Its possible triggers are recurrent minimal trauma, a habit or compulsive need to...
Get full text
Article -
10
Differences of hip involvement in systemic and non-systemic juvenile idiopathic arthritis by L. S. Sorokina, I. S. Avrusin, R. K. Raupov, N. T. Garipova, M. M. Gharabaghtsyan, S. V. Khrypov, M. A. Kaneva, E. A. Isupova, E. V. Gaidar, I. A. Chikova, M. F. Dubko, V. V. Masalova, T. S. Likhacheva, L. S. Snegireva, O. V. Kalashnikova, M. M. Kostik
Published 2022-03-01Systemic corticosteroids are continued to be administered in juvenile idiopathic arthritis (JIA) patients, especially in systemic JIA (sJIA), despite the ability of biologic therapy. One of the complications of long-term CS treatment is delayed hip arthritis development with risk of secondary hip os...
Get full text
Article -
11
Use of Implantable Venous Port Systems in the Treatment of Children with Orphan Diseases (Mucopolysaccharidosis and Pompe Disease): Case Series by M. Yu. Rykov, I. V. Filinov, E. I. Petrov, N. D. Vashakmadze, A. K. Gevorkyan, E. N. Arkhipova, I. V. Sil’nova, E. N. Basargina, N. V. Buchinskaya, A. I. Ivanov, E. A. Isupova, M. M. Kostik, N. A. Abramova, O. V. Kalashnikova, V. G. Chasnyk, A. E. Aleksandrov, D. A. Morozov, V. G. Polyakov
Published 2015-09-01Many orphan diseases in children require life-long and regular intravenous enzyme replacement therapy. The article describes the first Russian practice of implanting venous port systems in 12 patients with type I and II mucopolysaccharidosis and Pompe disease (6 months to 17 years old) to create lon...
Get full text
Article -
12
Experience in the diagnosis and treatment of Kawasaki disease in the Saint-Petersburg State Pediatric Medical University Clinic and Saint Petersburg City Children’s Hospital One by A. V. Santimov, R. A. Rupp, I. G. Alekseev, N. N. Plutova, E. A. Moskvina, M. K. Kruchina, A. N. Tarasenko, N. E. Sokolova, E. A. Savelyeva, I. Yu. Bogdanov, D. V. Ivanov, T. I. Kandrina, O. V. Kopanevich, A. Ya. Grafskaya, N. A. Ignatyeva, D. B. Pulukchu, N. V. Pavlova, I. V. Solodkova, O. V. Kalashnikova, T. L. Kornishina, M. F. Dubko, V. G. Chasnyk, M. M. Kostik
Published 2017-09-01Kawasaki disease (KD) is acute systemic vasculitis of unknown etiology. Approximately 20–25% of untreated patients develop coronary artery changes with a range of severity from asymptomatic coronary artery dilatation to giant coronary artery aneurysms with thrombosis, myocardial infarction, and sudd...
Get full text
Article